Nextech Trims Kymera at a Recent High — think Foolishly before acting. | The Motley Fool
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Source: The Motley Fool
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.